Effectiveness of Aspirin in COPD: Biases in the Observational Studies

References

• Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310:591–608. DOI:10.1001/jama.2013.13805
   PubMed Web of Science ®Google Scholar
• Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640–2646. DOI:10.1378/chest.128.4.2640
   PubMed Web of Science ®Google Scholar
• Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560. DOI:10.1016/j.jacc.2006.04.039
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48. DOI:10.1186/1471-2466-12-48
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-Severe COPD. N Engl J Med. 2014;370(23):2201–2210. DOI:10.1056/NEJMoa1403086
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019;381(24):2304–2314. DOI:10.1056/NEJMoa1908142
   PubMed Web of Science ®Google Scholar
• Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration. 2010;80(1):3–7. DOI:10.1159/000315387
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P. Beta-Blockers in COPD: a methodological review of the observational studies. COPD. 2018;15(5):520–525. DOI:10.1080/15412555.2018.1554637
   PubMedGoogle Scholar
• Sin DD. The devastating power of platelets in COPD exacerbations: can aspirin save lives in COPD? Thorax. 2014;69(7):603–604. DOI:10.1136/thoraxjnl-2014-205329
   PubMed Web of Science ®Google Scholar
• Pavasini R, Biscaglia S, d’Ascenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2016;13(4):509–514. DOI:10.3109/15412555.2015.1099620
   PubMedGoogle Scholar
• Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects Meta-analyses. BMJ. 2011;342:d549. DOI:10.1136/bmj.d549
   PubMed Web of Science ®Google Scholar
• Balduzzi S, Rücker G, Schwarzer G. How to perform a Meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–160. DOI:10.1136/ebmental-2019-300117
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Soft. 2010;36(3):1–48.
   Google Scholar
• Gordon M, Lumley T. Forestplot: advanced forest plot using ‘grid’ graphics. R package version 1.10.1. 2020. https://cran.r-project.org/web/packages/forestplot/forestplot.pdf
   Google Scholar
• Aaron CP, Schwartz JE, Hoffman EA, et al. A longitudinal cohort study of aspirin use and progression of emphysema-like lung characteristics on CT imaging: the MESA lung study. Chest. 2018;154(1):41–50. DOI:10.1016/j.chest.2017.11.031
   PubMed Web of Science ®Google Scholar
• McKeever TM, Lewis SA, Smit HA, et al. The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. Am J Respir Crit Care Med. 2005;171(9):966–971. DOI:10.1164/rccm.200409-1269OC
   PubMed Web of Science ®Google Scholar
• Kunadian V, Wilson N, Stocken DD, et al. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. ERJ Open Res. 2019;5(3):00110–2019. DOI:10.1183/23120541.00110-2019
   PubMedGoogle Scholar
• Yayan J. No significant detectable anti-infection effects of aspirin and statins in chronic obstructive pulmonary disease. Int J Med Sci. 2015;12(3):280–287. DOI:10.7150/ijms.11054
   PubMed Web of Science ®Google Scholar
• Mallah H, Ball S, Sekhon J, et al. Platelets in chronic obstructive pulmonary disease: an update on pathophysiology and implications for antiplatelet therapy. Respir Med. 2020;171:106098. DOI:10.1016/j.rmed.2020.106098
   PubMed Web of Science ®Google Scholar
• Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–283. DOI:10.1183/09031936.00106406
   PubMed Web of Science ®Google Scholar
• Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549. DOI:10.1136/bmj.d2549
   PubMed Web of Science ®Google Scholar
• Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715–720. DOI:10.1164/rccm.201208-1565OC
   PubMed Web of Science ®Google Scholar
• Harrison MT, Short P, Williamson PA, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609–615. DOI:10.1136/thoraxjnl-2013-203996
   PubMed Web of Science ®Google Scholar
• Campo G, Pavasini R, Malagu M, et al. Relationship between troponin elevation, cardiovascular history and adverse events in patients with acute exacerbation of COPD. COPD. 2015;12(5):560–567. DOI:10.3109/15412555.2014.995293
   PubMedGoogle Scholar
• Goto T, Faridi MK, Camargo CA, et al. The association of aspirin use with severity of acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study. NPJ Prim Care Respir Med. 2018;28(7). DOI:10.1038/s41533-018-0074-x
   PubMedGoogle Scholar
• Fawzy A, Putcha N, Aaron CP, et al. Aspirin use and respiratory morbidity in COPD: a propensity score-matched analysis in subpopulations and intermediate outcome measures in COPD study. Chest. 2019;155(3):519–527. DOI:10.1016/j.chest.2018.11.028
   PubMed Web of Science ®Google Scholar
• Ellingsen J, Johansson G, Larsson K, et al. Impact of comorbidities and commonly used drugs on mortality in COPD - Real-World data from a primary care setting. Int J Chron Obstruct Pulmon Dis. 2020;15:235–245. DOI:10.2147/COPD.S231296
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492–499. DOI:10.1093/aje/kwm324
   PubMed Web of Science ®Google Scholar
• Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49–53. DOI:10.1164/rccm.200210-1231OC
   PubMed Web of Science ®Google Scholar
• Samet JM. Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! Am J Respir Crit Care Med. 2003;168(1):1–2. DOI:10.1164/rccm.2304004
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241–249. DOI:10.1002/pds.1357
   PubMed Web of Science ®Google Scholar
• Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology. 2003;14(3):300–306.
   PubMed Web of Science ®Google Scholar
• Cole SR, Platt RW, Schisterman EF, et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol. 2010;39(2):417–420. DOI:10.1093/ije/dyp334
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Schisterman EF, Hernán MA. The birth weight "paradox" uncovered? Am J Epidemiol. 2006;164(11):1115–1120. DOI:10.1093/aje/kwj275
   PubMed Web of Science ®Google Scholar
• Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? Ann Epidemiol. 2015;25(5):342–349. DOI:10.1016/j.annepidem.2015.02.008
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–537. DOI:10.1183/09031936.00128914
   PubMed Web of Science ®Google Scholar
• Festic E, Bansal V, Gupta E, et al. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD. 2016;13(3):312–326. DOI:10.3109/15412555.2015.1081162
   PubMedGoogle Scholar
• Suissa S. Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias? Eur Respir J. 2019;53(2):1802112. DOI:10.1183/13993003.02112-2018
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. DOI:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Bustamante-Fermosel A, De Miguel-Yanes JM, Duffort-Falcó M, et al. Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features. Am J Emerg Med. 2007;25(5):515–522. DOI:10.1016/j.ajem.2006.09.014
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011;37(3):508–515. DOI:10.1183/09031936.00043710
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. DOI:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - What is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297. DOI:10.1056/NEJMsb1609216
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057. DOI:10.1183/16000617.0057-2018
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100(8):793–798. DOI:10.1161/01.CIR.100.8.793
   PubMed Web of Science ®Google Scholar
• Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. DOI:10.1371/journal.pone.0037483
   PubMed Web of Science ®Google Scholar
• Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006–1012. DOI:10.1378/chest.06-1997
   PubMed Web of Science ®Google Scholar